ADARx Pharmaceuticals filed for an initial public offering.
The late-stage biotechnology company did not say how many shares it would sell or at what price, according to a Friday filing with the Securities and Exchange Commission.
It applied to list shares on the Nasdaq Global Market under the symbol ADRX.
ADARx focuses on siRNA therapeutics and has five programs in its pipeline addressing several indications, including obesity, Alzheimer's disease, and strokes, according to the filing.
The company said it would use proceeds from the IPO to advance the development of its programs and conduct additional research and development efforts.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.